STAT+: Pharmalittle: Medicare proposes to restrict coverage of Biogen Alzheimer’s drug; Pfizer to cut its U.S. sales staff

Hello, everyone, and welcome to the middle of the week. You made it this far, so why not continue, yes? Perhaps a cup or two of stimulation is in order. Our choice today is stroopwafel. As you know, a prescription is not required. So feel free to indulge as you attack the laundry list of meetings and deadlines that await. Meanwhile, we have once again assembled a list of tidbits for you to peruse and help you on your way. Hope you have a smashing day and, as always, do drop us a line when you hear something interesting. …

Medicare plans to cover the controversial Biogen (BIIB) Alzheimer’s drug, but only for certain patients enrolled in clinical trialsSTAT tells us. The proposed move would likely mean some patients will not be able to access the drug, called Aduhelm, which is the first Alzheimer’s treatment approved in nearly two decades. Since it was endorsed last June by the U.S. Food and Drug Administration, doctors and scientists have raised questions about whether it actually works, government watchdogs have begun investigating whether the FDA followed proper approval procedures, and policy experts have questioned whether it is effective enough to justify its $28,000 price tag.

Continue to STAT+ to read the full story…

STAT+: Pharmalittle: Medicare proposes to restrict coverage of Biogen Alzheimer’s drug; Pfizer to cut its U.S. sales staff

Leave a Reply

Your email address will not be published. Required fields are marked *

Scroll to top